Market closedNon-fractional

Rocket Pharmaceuticals/RCKT

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Rocket Pharmaceuticals

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.

Ticker

RCKT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Cranbury, United States

Employees

268

RCKT Metrics

BasicAdvanced
$1.8B
Market cap
-
P/E ratio
-$2.85
EPS
1.11
Beta
-
Dividend rate
$1.8B
1.11
10.473
10.283
5.227
5.084
-141.02%
-32.64%
-55.38%
4.1
4.8
-8.36
-13.69%
1.54%

What the Analysts think about RCKT

Analyst Ratings

Majority rating from 15 analysts.
Buy

RCKT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$62M
4.03%
Profit margin
0.00%
NaN%

RCKT Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 3.06%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.82
-$0.75
-$0.64
-$0.66
-
Expected
-$0.79
-$0.81
-$0.79
-$0.68
-$0.72
Surprise
3.80%
-7.23%
-18.56%
-3.06%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Rocket Pharmaceuticals stock?

Rocket Pharmaceuticals (RCKT) has a market cap of $1.8B as of July 05, 2024.

What is the P/E ratio for Rocket Pharmaceuticals stock?

The price to earnings (P/E) ratio for Rocket Pharmaceuticals (RCKT) stock is 0 as of July 05, 2024.

Does Rocket Pharmaceuticals stock pay dividends?

No, Rocket Pharmaceuticals (RCKT) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Rocket Pharmaceuticals dividend payment date?

Rocket Pharmaceuticals (RCKT) stock does not pay dividends to its shareholders.

What is the beta indicator for Rocket Pharmaceuticals?

Rocket Pharmaceuticals (RCKT) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Rocket Pharmaceuticals stock

Buy or sell Rocket Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing